Bionano Genomics Q2 EPS $(1.24) Misses $(1.03) Estimate, Sales $8.66M Beat $8.29M Estimate
Portfolio Pulse from bharat@benzinga.com
Bionano Genomics reported Q2 losses of $(1.24) per share, missing the analyst consensus estimate of $(1.03) by 20.39%. This is a significant decrease from the same period last year. However, the company's quarterly sales of $8.66 million beat the analyst consensus estimate of $8.29 million by 4.49%, marking a 29.87% increase from last year.
August 09, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bionano Genomics' Q2 earnings per share missed estimates, but sales exceeded expectations. This mixed result could lead to uncertainty in the market.
Bionano Genomics' Q2 earnings per share missed the analyst consensus estimate by 20.39%, which could negatively impact the stock. However, the company's sales exceeded estimates, which could offset some of the negative impact. The mixed results could lead to uncertainty in the market, making it difficult to predict the short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100